Future prospects In order to provide appropriate therapy for osteoporosis, it is necessary to better define
the characteristics of each drug, and large-scale long-term follow-up is required for accumulation of a sufficient number of events because of the relatively low incidence of hip fracture. A prospective international cohort study (Global Longitudinal Study of Osteoporosis in Women) [27] was started in 2006, with the aim of following approximately 60,000 women aged 55 or older for 5 years. Such efforts are expected to clarify the characteristics of drugs for osteoporosis therapy, including ZD1839 molecular weight risedronate. Acknowledgments We are grateful to the following investigators and physicians for their contributions to our study. Coordinating investigators: Masayuki Egashira and Hiroshi Enomoto (Department of Orthopaedic Surgery, Nagasaki University School of Medicine) Physicians cooperating with the study: Yuji Sugitani, Narihiro Okazaki, Atushi Tagami,
Shinichi Nakahara, Toshiyuki Kumashiro, Hidetoshi Tanaka, Akihiko Tokuda (Department of Orthopaedic Surgery, Nagasaki Rosai Hospital), Shuji Nakanishi (Department of Orthopaedic Surgery, Nagasaki National Hospital), Taketoshi Date (Department of Orthopaedic Surgery, St. Francis Hospital), BKM120 research buy Kazuyoshi Uchihashi, Kyota Nishifuru, Yoshihiro Nozaki, Ai Mori (Department of Orthopaedic Surgery, National Hospital Organization Nagasaki Medical Center), Masahiko Okumura (Department of Orthopaedic Surgery, Wajinkai Hospital), Toshihiro Sadamatsu (Department of Orthopaedic Surgery, Sadamatsu Hospital), Masaya Shiraishi, Takashi Tamai, Shoichi Kuba (Department of Orthopaedic Surgery, Nagasaki Prefecture Shimabara Hospital), Koichiro Tashiro (Department of Orthopaedic Surgery, Nagasaki Memorial Hospital), Tomoyuki Taura, Itaru Yoda, Kenichi Kidera (Department of Orthopaedic Surgery, Nagasaki
Municipal Hospital), Shinji Adachi, Tomohiko Asahara, Masato Tomita, Kazuhiro Takahara (Department of Orthopaedic Surgery, Nagasaki Prefecture Tsushima Izuhara Hospital), Seiichirou Watanabe, Ritsu Tsujimoto (Department of Orthopaedic Surgery, Isahaya Health Insurance Dichloromethane dehalogenase General Hospital), Kouichi Adachi, Chikara Miyamoto, Hirohumi Doukawa, Masakazu Murata (Department of Orthopaedic Surgery, Nagasaki Yurino Hospital), Masayasu Sugiyama (Department of Orthopaedic Surgery, Juzenkai Hospital), Goji Chiba, Kenshiro Takaki (Department of Orthopaedic Surgery, Nishiisahaya Hospital), Noboru Yamamoto, Kenji Kumagai (Department of Orthopaedic Surgery, Japan Seafarers Relief Association Nagasaki Hospital) Affiliations are as at the time of conducting the study and are listed in random order. Funding/support This study was supported by Takeda Pharmaceutical Co., Ltd., Osaka, Japan. Conflicts of interest None.